Daily Stock List
ThermoEnergy Corp. (TMEN)
Stocks That Move, WallStreetGrand, and Lebed.biz reported earlier on ThermoEnergy Corp. (TMEN), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
ThermoEnergy Corp. is a diversified technologies company with corporate headquarters in Worcester, Massachusetts. They engage in the global development, sales and commercialization of patented and/or proprietary municipal and industrial wastewater treatment and power generation technologies. Founded in 1988, ThermoEnergy's mission is to continue to grow their market share and technological leadership within the global municipal/industrial wastewater treatment and power generation industries. The Company’s shares trade on the OTCBB.
ThermoEnergy’s clean combustion technology, Pressurized Oxy-Combustion (POXC™), will allow power producers and manufacturers that rely on conventional fossil fuels to take advantage of cheaper energy sources. This is while eliminating virtually all air emissions, as well as achieving full CO2 capture. The Company is pursuing the commercialization of POXC™ through the Unity Power Alliance.
Combustion and emission control strategies of a pressurized oxy-combustion (POXC™) system differs greatly from those employed at ambient conditions. The elevated system pressure allows for the capture of pollutants and recovering the latent heat from water entrained or produced in the combustion process by shifting the temperatures at which water, CO2, mercury and acid gases condense.
This enables POXC™ to recover the pollutants in the aqueous phase, including CO2, in clean pressurized liquid form ready for sequestration or beneficial reuse. On top of that, the estimation is that pressurized oxy-combustion increases power plant efficiency between 5 and 6 percent over most atmospheric combustion technologies, including atmospheric oxy-combustion.
ThermoEnergy’s award-winning wastewater recovery systems provide premier process economics and environmental compliance for an assortment of industrial and municipal water treatment facilities. Their water division specializes in custom-designed, turn-key solutions for a broad spectrum of clients. Moreover, the Company has established an extensive network of independent dealers and representatives throughout the United States.
In June, ThermoEnergy and ITEA S.p.A. announced that they will work together to promote, finance, design and construct a 50 Megawatt (MW) pilot plant and a 320 MW commercial facility in the United States using the clean coal technology called pressurized oxy-combustion. The objective is to accelerate the development of coal-fired emissions-free electricity generation. The clean coal technology will be developed and marketed by Unity Power Alliance LLC, a joint venture between ITEA and ThermoEnergy. ITEA has proven industrial experience with flameless pressurized oxy-combustion. They already operate a 5 MW thermal energy (MWth) in Italy that tests a broad array of fuels.
ThermoEnergy Corp. (TMEN), closed Thursday’s trading session at $0.12, up 15.00%, on 533,169 volume with 39 trades. The average volume for the last 60 days is 131,080. The 52-week low/high is $0.08/$0.27.
ESP Resources, Inc. (ESPI)
SeriousTraders, FeedBlitz, SmallCapVoice, Ceocast News, StockRich, HotOTC, MadPennyStocks, PennyInvest, CoolPennyStocks, BullRally, PennyStockVille, and StockEgg reported earlier on Wallbridge Mining Co. Ltd. (WM.TO), and we highlight the Company, here at the QualityStocks Daily Newsletter.
Trading on the OTCBB, ESP Resources, Inc. is an oil and gas services company. Through their wholly owned subsidiary, ESP Petrochemicals, Inc., they manufacture, blend, distribute, and market specialty chemicals and analytical services to the oil and gas industry. The wholesale division of the Company supplies specialty chemicals to a number of retailers operating in West Africa. ESP Resources has their headquarters in Scott, Louisiana.
The Company supplies retail and wholesale specialty chemicals for an assortment of oil field applications. These include production, drilling, waste remediation, cleaning, and waste water treatment. From their blending and distribution facilities, ESP Resources distributes their product line throughout the oil and gas producing regions of Louisiana, Texas, Mississippi, Alabama, Arkansas and Oklahoma, both onshore and offshore.
ESP Resources operates an 11,000 square foot blending and distribution facility in addition to outdoor storage used to supply their specialty chemicals in Scott, Louisiana for a variety of oil and gas field applications. At present, the Company services their customers out of five district offices. These are in Scott, Louisiana; Guy, Arkansas; Longview, Texas; Victoria, Texas, as well as Pharr, Texas.
Earlier, ESP Resources announced that on May 11, 2012, the Company, by way of their newly-formed and wholly owned subsidiary, ESP Corporation, S.A. (ESP), a company incorporated under the laws of Panama, entered into a shareholders' agreement to form a joint venture called ESP KUJV Limited with Komo Umbrella Joint Venture Limited (KUVJ), a company incorporated in Papua New Guinea (PNG), for the development of the Komo international airport. Owned 30 percent by KUJV and 70 percent by ESP, respectively, ESP KUJV formed to pursue, undertake and realize business opportunities within the Komo project area in PNG.
Yesterday, ESP Resources announced the formation of a new business division, ESP Facility & Pipeline Services, Inc. (ESP FPS), which is already seeing substantial growth. ESP FPS provides services for the upstream, midstream and downstream sectors of the energy industry. Services include Asset Management, Gas Dehydration Unit Management, Operating Personnel Training, Decommissioning and Asset Removal Support Services, Nitrogen, Air and Compression Services, as well as other services, both onshore and offshore. Currently, ESP FPS is expanding services to the Eagle Ford and Bakken Shale plays. Internationally, long-term projects are undergoing assessment in West Africa and the Middle East.
ESP Resources, Inc. (ESPI), closed Thursday’s session at $0.13, up 12.61%, on 1,011,864 volume with 73 trades. The average volume for the last 60 days is 119,255. The 52-week low/high is $0.07/$0.20.
Pelangio Exploration, Inc. (PX.V)
We are highlighting Pelangio Exploration, Inc. (PX.V) today, here at the QualityStocks Daily Newsletter.
Pelangio Exploration, Inc. is a junior gold exploration company that lists on the TSX Venture Exchange. The Company acquires and explores camp-sized land packages in world-class gold belts. Pelangio Exploration primarily operates in Ghana, West Africa. Pelangio consistently focuses on acquiring large land packages in existing gold camps. Incorporated in 2008, the Company is based in Milton, Ontario.
Ghana is Africa's second-largest gold producing country after South Africa. Close to 60 million ounces of gold have been mined in Ghana over the last century, and Gold reserves and resources are estimated at well over 100 million ounces.
Pelangio Exploration is exploring two 100 percent-owned camp-sized properties. One is the 100 km2 Manfo Property, the site of five recent near-surface, high grade and bulk tonnage, gold discoveries. The other is the 290 km2 Obuasi Property, located four kilometers on strike and adjacent to AngloGold Ashanti's prolific, high-grade Obuasi Mine, which has produced more than 30 million ounces of gold since 1897.
Last week, Pelangio Exploration announced preliminary scoping metallurgical test results from four composite samples taken primarily from the Pokukrom East gold zone at the Manfo Property in Ghana. The testwork was undertaken by SGS Mineral Services in Lakefield, Ontario, in the first quarter of 2012.
Highlights of the Metallurgical Testwork Report from the Pokukrom East zone include composite samples that present mineralization that is expected to achieve 84-94 percent gold recovery via a conventional free milling gold circuit at a grind size of 80 percent passing 75 micron, as determined by 48 hour leach tests with the recovery of 21-50 percent through gravity separation alone. The metallurgy of the material appears amenable to a standard free milling gold flowsheet. It is similar to some deposits in the region presently in production.
All four metallurgical sample types submitted for testing demonstrated a variance in the measured gold grade compared to the exploration half core assays for the same intervals. The Sericite Low-Grade Sulphide metallurgical sample increased by 51.4 percent to 2.71 g/t Au, the Sericite High-Grade Sulphide increased by 77.8 percent to 12.5 g/t Au, the Oxidized Zone increased by 25.8 percent to 1.22 g/t Au, while the Hematite Low-Grade Sulphide decreased by 18 percent to 1.32 g/t Au.
Pelangio Exploration, Inc. (PX.V), closed Thursday’s trading session at $0.28, even with yesterday’s close, on 68,785 volume. The 52-week low/high is $0.28/$0.68.
CombiMatrix Corp. (CBMX)
SmarTrend Newsletters and AllPennyStocks reported previously on CombiMatrix Corp. (CBMX), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
CombiMatrix Corp., through their wholly owned subsidiary, CombiMatrix Molecular Diagnostics, Inc. (CMDX), is a molecular diagnostics laboratory which offers DNA-based testing services to the prenatal, pediatric and oncology markets. The Company performs genetic testing utilizing Microarray, FISH, PCR and G-Band Chromosome Analysis. Founded in 1995, CombiMatrix has their headquarters in Irvine, California.
CombiMatrix is a CLIA-certified & CAP accredited commercial clinical laboratory. CombiMatrix’s customers include healthcare institutions, such as hospitals and clinics, physicians, and individual patients; and organizations, such as commercial insurance companies, as well as government payors, including Medicare and Medicaid.
The Company’s CMDX subsidiary offers prenatal and pediatric testing services for the detection of abnormalities of genes at the DNA level beyond what can undergo identification through traditional technologies. CMDX was also the first commercial clinical laboratory in the U.S to make comprehensive DNA-based genomic analysis of solid tumors, including breast, colon, lung, prostate and brain tumors, available to oncology patients and medical professionals.
CombiMatrix has established their company as an industry leader in microarray-based clinical testing. They have accomplished this by their core team of arrayCGH-pioneering physicians, scientists and technicians and their commitment to client and patient-focused service. The Company looks for strategic partnerships. They seek affiliations with other laboratories and pathology groups that would like to offer the Company’s testing services to their own physician and patient populations.
The Company’s oncology diagnostic tests include DNAarrayHeme Profile test, which addresses common hematological malignancies with an emphasis on chronic lymphocytic leukemia; DNAarrayHER2 PRO, which determines HER2 status; and DNAarrayTumor Profile for DNA-based genomic analysis of solid tumors.
In May, CombiMatrix reported that total revenues for the first quarter of 2012 increased 36 percent to $1.2 million from $913,000 in the first quarter of 2011. The Company performed 1,377 billable diagnostic tests for 105 customers in the first quarter of 2012. This is in comparison to 958 tests for 86 customers in the first quarter of 2011.
Net loss from continuing operations during the first quarter of 2012 was $(2.4 million), or $(0.22) per basic and diluted share from continuing operations. This is compared to $(2.0 million), or $(0.26) per basic and diluted share from continuing operations in the first quarter of 2011. This increase was due primarily to increases in operating expenses in sales and marketing and general and administrative costs associated with increased headcount as well as increased recruiting costs associated with new Company Directors and a Chief Medical Officer, which were earlier announced.
CombiMatrix Corp. (CBMX), closed Thursday at $0.75, down 2.10%, on 18,768 volume with 23 trades. The average volume for the last 60 days is 4,109. The 52-week low/high is $0.73/$3.40.
Emperial Americas, Inc. (TEXX)
Stockhunter.us, HEROSTOCKS, Liquid Pennies, GoldminePennyStocks, AwesomePennyPicks, CashMoneyPlays, hyperspeedstocks, ExclusiveStockAlerts, and Streetwise Reports reported earlier on Emperial Americas, Inc. (TEXX), and we choose to highlight the Company today, here at the QualityStocks Daily Newsletter.
Emperial Americas, Inc., develops, imports, markets and supplies branded alcoholic beverages. The Company’s initial offerings are Tequila and Bourbon. Emperial Americas’ vision is to be the ultimate brand builders of the industry by engaging the consumer and commerce with unparalleled delivery. The Company’s shares trade on the OTC Bulletin Board. Emperial Americas has their corporate headquarters in Sarasota, Florida.
The design of the Company’s business model is to build powerful individual and independent brand identities within a balanced brand portfolio. This is by establishing a solid worldwide platform from which they will launch and develop new and existing brands. Emperial Americas’ brands include Distinguido Tequila, Broken Barrel Bourbon, and Independence Rye.
Earlier this year, the Company announced that through strategic partnerships with regional chain accounts and sponsorship programs including the AMF/Miss Geico Offshore racing and Indy-Lights, Tequila Distinguido will continue to be exposed and marketed as an ultra premium tequila. Emperial Americas will continue to execute their plan to enter key markets. These markets include Georgia, Nevada, Colorado, New York and California. The Company announced at the end of May that they entered into a multi-year sponsorship agreement with AMF/Miss GEICO Offshore Racing for the award winning tequila, Tequila Distinguido.
This week, Emperial Americas disclosed their financial projections for business operations going forward. Chief Executive Officer, Alonzo Pierce, said, "For weeks now we have been fine-tuning and reviewing our revenue projections and projected operating profits. As a result we are now releasing what we consider to an accurate picture of the company moving forward. Over the next four and one-half years, we are projecting $28,864,677 in Gross Sales with an operating profit of $5,547,350, which is a 19.2 percent profit margin. Based upon our current and projected inventory from existing brands and acquisitions in progress, along with the tremendous power from our distributors, we feel that the company is poised to capitalize on the spirits market."
Emperial Americas, Inc. (TEXX), closed Thursday’s trading session at $0.14, up 44.00%, on 978,083 volume with 192 trades. The average volume for the last 60 days is 24,261. The 52-week low/high is $0.03/$7.20.
Gravis Oil Corp. (GRAVF)
Today we are reporting on Gravis Oil Corp. (GRAVF), here at the QualityStocks Daily Newsletter.
Gravis Oil Corp. is an independent oil and gas company. They specialize in non-conventional oil and gas projects with a focus on heavy oil, with a current operational emphasis on the Deerfield area of Western Missouri in the U.S. The Company formerly went by the name MegaWest Energy Corp; they changed their name to Gravis Oil Corp. in June 2011. Incorporated in 2000, Gravis Oil has their headquarters in Calgary, Alberta. The Company lists on the OTC Bulletin Board.
The Company holds interests in various projects in Missouri, Kentucky, Montana, and Kansas. Recently, Gravis Oil announced that they entered into a non-binding Letter Of Intent (LOI) with Petro River Oil, LLC, a privately held Delaware limited liability company that would result in Gravis acquiring Petro for common stock, the name of Gravis changed, and the Company redomiciled to Delaware. The LOI also contemplates that the Board of Gravis will consist of 5 members, 4 of which will be nominated by Petro.
Petro River Oil is an emerging oil producer. They are focusing on liquid rich assets in the Southeast Kansas region of the Mississippi Lime. Petro River oil owns approximately 100,000 net acreage and legacy wells, with plans to begin production this month.
The intention is that post-transaction, current common shareholders of Gravis Oil will own approximately 2.5 percent of the issued and outstanding shares of the Company, holders of Gravis Preferred shares and notes approximately 22.5 percent, and holders of shares and notes of Petro approximately 75 percent. The Merger Transaction is subject to Gravis Oil shareholder approval.
Petro brings an exemplary leadership team to the Mississippi Lime. This includes Ruben Alba, Daniel Smith and Louis Vierma. Alba joined Petro River in 2011 after 13 years at Halliburton Energy Services and Superior Well Service. Smith joins Petro River from XTO Energy where he served as Operations Engineer. Vierma comes from Venezuela's PDVSA - the fourth largest oil company in the world - where he served in several leadership roles before being sworn in as the Director General of Hydrocarbons and External Director of PDVSA in 2003 including a role as Venezuela's Deputy Oil Minister to OPEC.
Gravis Oil Corp. (GRAVF), closed Thursday’s trading at $0.11, up 10.00%, on 80,700 volume with 11 trades. The average volume for the last 60 days is 2,692. The 52-week low/high is $0.002/$0.35.
AllEnergy Corp. (AFSE)
SmallCapVoice and FeedBlitz reported earlier on AllEnergy Corp. (AFSE), and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
AllEnergy Corp. is an international energy company engaging in the acquisition, development and production of oil and natural gas. The Company is aggressively pursuing the acquisition of domestic and international oil and gas properties with the intent of exploration, exploitation and development or enhancing existing production through employing modern developmental techniques.
The Company formerly went by the name ALL Fuels & Energy Co. They changed their name to All Energy Corp. in January of this year. AllEnergy lists on the OTCBB; the Company has their headquarters in Johnston, Iowa. AllEnergy has initial lease projects in Texas and Belize.
AllEnergy acquires and develops oil and gas leases which have "proven but undeveloped reserves" at the time of acquisition. These properties are not strategic to large exploration-oriented oil and gas companies. This strategy allows the Company to develop and produce oil and natural gas with significantly decreased risk, cost and time involved in traditional exploration.
In June, AllEnergy reported that they contracted the purchase of the Bell Lease located near Abilene, Taylor County, Texas. The purchase contains 40 acres with a producing oil well #1, rework well #2, and an additional drill site for well #3. Further to the lease, the Company acquired consent to inject salt water to a nearby salt water disposal well. The Bell Lease is adjacent to the Reddin unit. The Reddin has been in production for 70 years and has produced more than 6 million barrels of oil. AllEnergy has current yearly production of 3600 barrels on well #1 before improvements. The Company will rework well #2 and drill a new third well on the Bell lease next quarter.
In addition, last month, AllEnergy reported that they elected to participate in the Mahalec Lease located in DeWitt County, Texas. The 272 acre prospect has 12 drilling locations; it has potential gross reserves of 3.6 million barrels of oil and 6 BCF of natural gas, which equates to $302 million, based upon today's prices. The Company will have an approximate 5 percent Working Interest (WI) in this prospect.
AllEnergy Corp. (AFSE), closed Thursday’s trading session at $0.23, up 15.00%, on 38,344 volume with 38 trades. The average volume for the last 60 days is 91,481. The 52-week low/high is $0.03/$2.00.
TechPrecision Corp. (TPCS)
SmallCapVoice reported earlier on TechPrecision Corp. (TPCS), and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
TechPrecision Corp., via their wholly owned subsidiaries, Ranor, Inc., and Wuxi Critical Mechanical Components Co., Ltd., is an industry leading, global manufacturer of precision, large-scale fabricated and machined metal components and systems. The Company’s mission is to be the leading end-to-end global service provider to their markets by furnishing custom, fully integrated "turn-key" solutions for complete products that require custom fabrication, precision machining, assembly, integration, inspection, non-destructive evaluation and testing. Founded in February 2006, TechPrecision is based in Center Valley, Pennsylvania.
The Company’s products are used in diverse markets. These include renewable energy (solar and wind), medical, nuclear, defense, industrial, as well as aerospace. TechPrecision’s Ranor subsidiary was founded in 1956. Ranor specializes in large-scale, precision component fabrication for the Cleantech, energy, medical, aerospace, and defense sectors. Ranor has a number of ASME certifications, including an N-Stamp certification for nuclear components.
Founded in 2010, TechPrecision’s Wuxi Critical Mechanical Components (CMC) subsidiary was designed to meet the growing worldwide demand for an experienced, knowledgeable machining and distribution center in Asia, providing large-scale component fabrication solutions for the region's solar and wind power challenges. CMC employs one of the largest forges in the industry. CMC is positioned to provide companies with quality, durable, and efficient current and next-generation components that address their industry's specific needs.
Yesterday, TechPrecision announced that they received $2.3 million in orders from a sapphire customer. The new orders include $2.3 million in purchase orders against the previously announced $9.5 million ongoing purchase agreement from an existing customer to produce sapphire chambers at their Wuxi Critical Mechanical Components facility in China.
These units are in addition to $2.1 million in the previously announced backlog as of July 13, 2012, against the same $9.5 million purchase agreement. Therefore, TechPrecision has now received $4.4 million in aggregate orders under this purchase agreement. Production chambers will be shipped in the second and third quarters of fiscal 2013.
TechPrecision Corp. (TPCS), closed Thursday’s trading session at $0.70, up 16.67%, on 38,800 volume with 14 trades. The average volume for the last 60 days is 31,025. The 52-week low/high is $0.55/$1.70.
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.32, up 8.11%, on 77,542 volume with 26 trades. The stock’s average daily volume over the past 60 days is 185,856, and its 52-week low/high is $0.21/$1.00.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.
A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.
In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corporation's Co-Chairman and CEO Andrey Semechkin PhD Publishes Letter to Shareholders
International Stem Cell Corporation Featured in Stem Cell Technology's Bright Future Article on Seeking Alpha
International Stem Cell Corporation Reports Reaching Milestone in Its Cornea Program
Skinny Nutritional Corp. (SKNY)
The QualityStocks Daily Newsletter would like to spotlight Skinny Nutritional Corp. (SKNY). Today, Skinny Nutritional Corp. closed trading at $0.01, off by 1.33%, on 2,284,850 volume with 30 trades. The stock’s average daily volume over the past 60 days is 2,655,502, and its 52-week low/high is $0.0052/$0.068.
Skinny Nutritional Corp. (SKNY) has established their Skinny Water® brand as a clear alternative to other products in the enhanced water space, with the only true zero calorie, sugar, carb, sodium, and preservative-containing beverage available. Skinny Water's proprietary formulation of essential antioxidant agents, electrolytes, and the critical vitamins our bodies need in order to achieve optimal function, uses 100% natural flavors, no preservatives, no artificial colors, and only the best purified water.
The company has constructed a network of approximately 50 domestic distributors (with three more internationally), placing product on shelves approximately 15k stores across the United States. Derived from the natural flavors contained in fruits, Skinny Water represents a fortified, extremely low-impact, great-tasting array of beverages that provide a concentrated punch of the nutrients essential for a healthier lifestyle.
The company's strong emphasis on health, fitness, and community has served marketing initiatives very well. The new age beverage segment has seen increasing momentum in recent years, with just about every beverage company getting into the game, but none of them has the kind of no-nonsense product composition behind Skinny Water, something that appeals directly to the majority of the core consumer market.
Skinny Nutritional continues to build value around the Skinny Water brand, and today has numerous trademarks in the healthy beverage and snack food categories. As consumers migrate away from sugar based beverages and empty calories, Skinny Water is ideally positioned to benefit from positive market trends as management focuses on delivering exceptional value to shareholders. Disclaimer
Skinny Nutritional Corp. Blog
Skinny Nutritional Corp. News:
A&P's 275 Stores Continue Skinny Water's Mid-Atlantic Penetration
Skinny Nutritional Corp. Enters Into $15M Financing, Positions Company to Grow Skinny Brand Portfolio Nationally
Skinny Nutritional Corp. Enters Distribution Agreement With Michigan-Based D&B Grocers Wholesale, Inc.
GlobalWise Investments, Inc. (GWIV)
The QualityStocks Daily Newsletter would like to spotlight GlobalWise Investments, Inc. (GWIV). Today, GlobalWise Investments, Inc. closed trading at $1.60, off by 5.33%, on 500 volume with 1 trade. The stock’s average daily volume over the past 60 days is 3,987, and its 52-week low/high is $1.02/$1.87.
GlobalWise Investments, Inc. (GWIV), via wholly-owned subsidiary Intellinetics, Inc., is a leading-edge technology company focused on Enterprise Content Management (ECM) solutions for the digital age. The ECM industry continues to grow rapidly as a result of unrestricted proliferation of digital content within today's business environment. Leveraging its proprietary cloud-based computing software, GlobalWise is poised to capture a significant market share of this burgeoning industry.
GlobalWise's ECM service is delivered to customers via five unique delivery models which cover the spectrum of business needs: Cloud/Saas (Software as a Service), Hardware Vendor Integrated Service, Software Vendor Integrated Service, Premise (Client-Server), Hybrid (Premise & Cloud/Saas).This diversity gives advanced security & privacy features with an on-demand structure needed for large Tier 3 and Tier 4 businesses that are currently underserved by the market.
The Intellinetics platform defines a new industry benchmark and game-changing approach by combining advanced virtualization & automated content management with an open and service-oriented architecture using web services. The company provides strategies, tactics, and technologies used to manage paper and digital assets from capture to long-term archive, without the need for manual processes conducted by a full time employee.
GlobalWise's management boasts a combined total of over 60 years in ECM leadership and industry experience. The ECM industry is expected to exceed $5.1 billion by 2013 with Gartner predicting a compound annual growth rate of 9.5%. IBM Market Insights predicts adoption of cloud computing to grow by 26% CAGR between 2010 through 2013. Leveraging management and key department heads, Intellinetics has a strong foundation from which to capture significant market share within the lucrative $149 billion Business Software & Services industry. Disclaimer
GlobalWise Investments Company Blog
GlobalWise Investments News:
GlobalWise CEO to Be Featured Speaker at World Expo 2012 Conference
GlobalWise ECM Software Intellivue™ Named #1 at Prestigious Managed Printer Conference by "The Week in Imaging"
GlobalWise Reports on International Expansion Initiatives
Consorteum Holdings, Inc. (CSRH)
The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.09, even with yesterday's close. The stock’s average daily volume over the past 60 days is 80,525, and its 52-week low/high is $0.001/$0.018.
Consorteum Holdings, Inc. (CSRH) utilizes the most technically advanced global solutions available today. By working with a multitude of global technologies, Consorteum is able to create customized programs for maximum results. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new streams of revenue.
Through its exclusive software license with Tarsin Inc., the company leverages a team of software developers that understands the complexities of delivering digital media content across mobile handsets. Tarsin is capable of providing clients with integration and support for over 700 mobile carriers globally on a seamless and secure platform to take advantage of the increasing demand for rich mobile content.
Consorteum's flagship CAPSA technology platform brings a universal solution to the problems of wagering and betting on mobile devices. Multiple different operating systems, user interfaces, and form factors have created enormous barriers to launching commercial initiatives. But with CAPSA, gaming operators can now cost-effectively monetize innovative mobile wagering products and services quickly and robustly.
In addition to its mobile initiatives, Consorteum is also actively engaged in the financial industry, providing MasterCard solutions as well as loyalty and reward programs. The company has strategically designed its business initiatives to create repetitive transactions on an ongoing basis. Consorteum's goal is to have their customers think of them more as partners, rather than just technology providers, for longer-lasting, more profitable relationships. Disclaimer
Consorteum Holdings, Inc. Company Blog
Consorteum Holdings, Inc. News:
CORRECTION -- Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming
Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming
Consorteum Completes Acquisition of Tarsin Inc.
BSD Medical recently announced that its BSD-2000 Hyperthermia System has been purchased by the prestigious University of California San Francisco Medical Center. The system will now be available as a treatment option for the center’s patients.
One of the top 10 hospitals in the U.S., UCSF Medical Center is recognized around the world for its advanced patient care and cutting-edge technology. The center is one of the leading cancer care providers in the world. UCSF Medical Center’s Comprehensive Cancer Center was awarded the prestigious “comprehensive” designation from the National Cancer Institute and ranks sixth in the nation in NCI research grants. UCSF Medical Center employs more than 7,000 people at its numerous facilities.
UCSF has a longstanding history of providing cutting-edge therapies to patients. The center also recently purchased a BSD-500 Hyperthermia System from BSD Medical Corporation, and the company is pleased they will also be offering the BSD-2000’s pioneering capabilities to their patients.
The BSD-2000, which has been exclusively developed and patented by BSD, provides localized therapeutic heating (hyperthermia) through the application of radiofrequency (RF) energy. The system creates a central focus of energy that is capable of electronically focusing to target the shape, size, and location of a tumor, thereby providing dynamic control of the heating delivered to the tumor region. The system has Humanitarian Device Exemption (HDE) marketing approval from the FDA for use in conjunction with radiation therapy to treat cervical cancer patients who are not eligible for chemotherapy. Additionally, the BSD-2000 has CE Marking approval for commercial sale in Europe and many countries outside of the European Union.
BSD Medical Corporation is engaged in the development, manufacturing, marketing, and servicing of systems for the treatment of cancer and benign diseases by means of heat therapy delivered via RF and microwave energy. The company’s product lines include systems for treating both hyperthermia and ablation.
In use for several years in the U.S., Europe, and Asia, BSD’s hyperthermia cancer treatment systems are used for treating certain tumors with heat (hyperthermia) while simultaneously increasing the effectiveness of other therapies like radiation therapy. The company’s microwave ablation system has been developed as a standalone therapy for employing precision-guided microwave energy to destroy soft tissue.
BSD has developed substantial intellectual property and multiple products in the market, and the company has established distribution in the U.S., Europe, and Asia. Some of the company’s products have been granted regulatory approvals and clearances in the U.S., Europe, and China.
For more information, visit the company’s Web site at www.BSDMedical.com
Novavax is a clinical stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide. The company’s innovative technology platforms use virus-like particles (VLP) and recombinant nanoparticle technology to create geographic-specific vaccine solutions to combat various infectious diseases.
The company yesterday announced a clinical development partnership with PATH to develop its RSV (respiratory syncytial virus) vaccine to protect infants through maternal immunization in low-resource countries. PATH is an international non-profit organization that takes an entrepreneurial approach to developing and delivering lifesaving vaccines and devices in more than 70 countries. Novavax has been awarded approximately $2 million by PATH for initial funding to partially support a Phase II dose-ranging clinical trial in women of childbearing age for its RSV vaccine.
RSV is highly contagious and the most common cause of childhood respiratory infection globally, with 64 million cases, causing about 160,000 deaths every year. Sadly, at the moment, there is no approved RSV vaccine available on the market. This is the logic behind PATH’s $2 million partnership with Novavax after it saw the successful Phase I study. The Phase II study of the RSV vaccine, planned for later this year, will be designed to evaluate the immune response to different doses of this vaccine candidate in women of childbearing age.
If the results from the Phase II study are positive, PATH has the option to continue to partner with Novavax to provide support (perhaps as high as 50% of costs) commercialization of the vaccine. Novavax will retain global rights to commercialize the vaccine. The goal of the partnership would be to immunize pregnant women, such that high levels of RSV antibodies will be transmitted to their children. This will provide protection against infection during the early infancy period, when the disease is most likely to strike.
For additional information about Novavax, its RSV vaccine, and other products, please visit the company’s website at www.novavax.com
Sarepta Therapeutics is a biotechnology company focused on developing first-in-class RNA-based therapeutics which will improve or even save the lives of people affected by serious, life-threatening rare and infectious diseases. The company’s pipeline of drugs includes its lead program eteplirsen (for Duchenne muscular dystrophy) as well as potential treatments for some of the world’s most lethal infectious diseases.
The company announced today that its lead therapeutic drug for the Marburg Virus, AVI-7288, demonstrated up to 100% survival in a non-human primate study exploring the drug’s effect when treatment is delayed to various time points post-infection. The study also showed a significantly higher rate of survival among the primates treated with AVI-7288 when compared to the placebo-treated group when treatment was administered up to 96 hours after infection.
This study was conducted under a US Department of Defense contract and was managed by the Joint Project Manager Transformational Medical Technologies Project Management Office, which is a component of the Joint Program Executive Office for Chemical and Biological Defense. The work is a collaborative effort between Sarepta Therapeutics and scientists at the US Army Medical Research Institute of Infectious Diseases, the Department of Defense’s leading medical research laboratory for biological defense.
More specifically, the study showed a high degree of survival (between 83% and 100%) in each of four post-exposure cohorts that received daily treatments with AVI-7288 beginning 1, 24, 48, and 96 hours after infection. This compared to the zero percent survival rate in the placebo-treated control group. Currently at day 27, the study will continue to monitor the surviving primates until the study ends after day 41.
For additional information about Sarepta Therapeutics and its drug pipeline, please visit the company’s website at www.sareptatherapeutics.com
SaveDaily, a provider of low-cost mutual fund investing platforms used by financial institutions, today announced the appointment of Robert Roche as the company’s compliance officer and director of Small Account Strategy.
SaveDaily also announced that it has retained the compliance consulting services of National Regulatory Services (NRS) to ensure compliance in preparation for the growth curve the company expects to experience. NRS provides compliance and registration products and services that enable its clients to meet their regulatory requirement and minimize risk.
“We are very pleased and confident in the foundation we have set when it comes to complying with the complex and sophisticated financial regulatory structure we operate under. As we sign more marketing agreements with top financial institutions and begin seeing a strong growth curve, we want to stay ahead of the increased potential risk by ensuring strict compliance under existing and possible new regulations,” Jeff Mahony, CEO of SaveDaily stated in the press release. “Bringing Robert on as a dedicated compliance supervisor backed up by the excellent team at NRS, we are confident that our systems and processes will meet and exceed all requirements including SSAE 16.”
Roche has 20 years of experience in Financial Services and has worked with top banks and turnkey asset management providers to build-out some of the largest programs in the country. He recently served as director of Operations for a multi-billion dollar quantitative RIA firm offering sophisticated Value and ETF rotational strategies to institutions and private clients.
“This is an exciting company that is breaking down old investing models and bringing affordable, professionally managed investing to the masses. I am eager to work with a group like NRS to make SaveDaily’s business processes a case study in excellence for financial services controls and reporting standards. The fact that we are taking these steps clearly demonstrates our commitment to the investing public,” Roche stated.
For more information, visit www.savedaily.com
Today's Top 3
The QualityStocks Public Company Sponsor News